Evidence map›Paper›PMID 40842970›Full record

ReviewBladder cancer (Amsterdam, Netherlands)

Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management.

Nicholas I Simon, Andre R Kydd, Dilara Akbulut, David Takeda, Jaydira Del Rivero, Maria Merino, Bernadette Redd, Liza Lindenberg, Esther Mena, Elias Chandran and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bladder cancer (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nicholas I SimonGenitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-1259-9201
Andre R KyddGenitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
Dilara AkbulutLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
David TakedaGenitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
Jaydira Del RiveroPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Maria MerinoLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Bernadette ReddRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Liza LindenbergMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Esther MenaMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Elias ChandranGenitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
Sandeep GurramUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Salah BoudjadiGenitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
Scot NiglioGenitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
Parth SharmaDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-0647-4691
Anish ThomasDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Andrea B ApoloGenitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

Funding

Bladder Cancer ProgramZIABC011351 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APOLO, ANDREA · 2010 to 2025
$9.4M
Rare GU tumors projectsZIABC011928 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APOLO, ANDREA · 2019 to 2025
$4.6M
Intramural NIH HHS ZIA BC011351Intramural NIH HHS ZIA BC011928
6 · The paper itself

Abstract

Small cell carcinoma of the bladder (SCCB) is a rare, aggressive malignancy that accounts for less than 1% of all bladder cancers. In this report, we highlight the clinical manifestations of SCCB (including epidemiology, cystoscopic and imaging findings), summarize insights into the molecular mechanisms underlying its pathophysiology, detail current methods of staging, review local and systemic treatment, and explore novel agents currently in clinical development. Most of the regimens used for SCCB treatment are extrapolated from small cell lung cancer, a more common cancer that shares the neuroendocrine and aggressive clinical phenotype of SCCB. Greater preclinical research can help to elucidate pertinent similarities and differences between SCCB and other neuroendocrine cancers as well as reveal new therapeutic targets, while increased participation of patients with SCCB in clinical trials may provide additional treatment options for patients with this aggressive cancer.

Indexed as

high grade neuroendocrine carcinomarare genitourinary malignancysmall cell carcinoma of the bladder

Identifiers

PMID40842970
PMCPMC12365374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.